Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III Innovate
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
01 11 2021
01 11 2021
Historique:
received:
17
05
2021
revised:
09
07
2021
accepted:
05
08
2021
pubmed:
13
8
2021
medline:
1
4
2022
entrez:
12
8
2021
Statut:
ppublish
Résumé
The first report from the open-label substudy of the phase III iNNOVATE study (PCYC-1127; NCT02165397) demonstrated that single-agent ibrutinib was efficacious and well tolerated in patients with heavily pretreated, rituximab-refractory Waldenström macroglobulinemia. Results from the final analysis are now reported. Ibrutinib 420 mg was administered once daily to patients ( After a median follow-up of 58 months (range: 9-61), median PFS was 39 months [95% confidence interval (CI): 25-not evaluable]; 60-month PFS rate was 40%. In MYD88 In the final analysis from iNNOVATE, single-agent ibrutinib continued to show sustained efficacy in patients with heavily pretreated, rituximab-refractory Waldenström macroglobulinemia.
Identifiants
pubmed: 34380643
pii: 1078-0432.CCR-21-1497
doi: 10.1158/1078-0432.CCR-21-1497
pmc: PMC9401517
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
Piperidines
0
ibrutinib
1X70OSD4VX
Rituximab
4F4X42SYQ6
Adenine
JAC85A2161
Banques de données
ClinicalTrials.gov
['NCT02165397']
Types de publication
Clinical Trial, Phase III
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5793-5800Informations de copyright
©2021 The Authors; Published by the American Association for Cancer Research.
Références
N Engl J Med. 2015 Apr 9;372(15):1430-40
pubmed: 25853747
Br J Haematol. 2019 Nov;187(3):356-363
pubmed: 31267520
Blood Adv. 2019 Jun 25;3(12):1799-1807
pubmed: 31196847
Lancet Haematol. 2020 Nov;7(11):e827-e837
pubmed: 33091356
Blood Adv. 2020 Dec 8;4(23):6009-6018
pubmed: 33284944
Blood. 2020 Oct 29;136(18):2038-2050
pubmed: 32731259
Blood. 2013 Aug 15;122(7):1222-32
pubmed: 23836557
Lancet Oncol. 2017 Feb;18(2):241-250
pubmed: 27956157
Oncotarget. 2018 Dec 7;9(96):36824-36825
pubmed: 30627320
Blood. 2018 Apr 26;131(17):1910-1919
pubmed: 29437592
N Engl J Med. 2015 Aug 6;373(6):584-6
pubmed: 26244327
J Clin Oncol. 2022 Jan 1;40(1):52-62
pubmed: 34606378
Leukemia. 2020 Mar;34(3):787-798
pubmed: 31628428
Blood. 2014 May 1;123(18):2791-6
pubmed: 24553177
J Clin Oncol. 2021 Feb 20;39(6):565-575
pubmed: 32931398
N Engl J Med. 2018 Jun 21;378(25):2399-2410
pubmed: 29856685
J Clin Oncol. 2000 Jan;18(1):214-26
pubmed: 10623712
Am J Hematol. 2018 Aug;93(4):511-517
pubmed: 29280186